Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis

MLA

Maria De Santis, et al. “Serum IL-23 Levels Reflect a Myeloid Inflammatory Signature and Predict the Response to Apremilast in Patients with Psoriatic Arthritis.” Frontiers in Immunology, vol. 15, Dec. 2024. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1455134.

APA

Maria De Santis, Antonio Tonutti, Natasa Isailovic, Francesca Motta, Radu Marian Rivara, Rita Ragusa, Giacomo M. Guidelli, Marta Caprioli, Angela Ceribelli, Daniela Renna, Nicoletta Luciano, & Carlo Selmi. (2024). Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1455134

Chicago

Maria De Santis, Antonio Tonutti, Natasa Isailovic, Francesca Motta, Radu Marian Rivara, Rita Ragusa, Giacomo M. Guidelli, et al. 2024. “Serum IL-23 Levels Reflect a Myeloid Inflammatory Signature and Predict the Response to Apremilast in Patients with Psoriatic Arthritis.” Frontiers in Immunology 15 (December). doi:10.3389/fimmu.2024.1455134.